A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain

Bibliography

• Acetaminophen overdose and liver injury – background and options for reducing injury. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf
   Google Scholar
• Medicine use and shifting costs of healthcare: A review of the use of medicines in the united states in 2013 [Internet]. Available from: http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=2684d47626745410VgnVCM10000076192ca2RCRD&vgnextchannel=736de5fda6370410VgnVCM10000076192ca2RCRD&vgnextfmt=default
   Google Scholar
• U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. NHSDA Series H-22, DHHS Publication No SMA 03–3836. Office of Applied Studies; Rockville, MD: 2003. Results from the 2002 National Survey on Drug Use and Health: National Findings. Table 1.107 A & B
   Google Scholar
• Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Services and Quality. 2013 Tables: Illicit Drug Use - 1.47 to 1.92 (PE). Table 1.89A - Nonmedical Use of Specific Pain Relievers in Lifetime, by Age Group: Numbers in Thousands, 2012 and 2013 Available from: http://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabsPDFWHTML2013/Web/HTML/NSDUH-DetTabsSect1peTabs47to92-2013.htm [Last accessed 16 January 2015]
   Google Scholar
• Throckmorton DC; Re-scheduling prescription hydrocodone combination products. FDA Voice. Available from: http://blogs.fda.gov/fdavoice/index.php/2014/10/re-scheduling-prescription-hydrocodone-combination-drug-products-an-important-step-toward-controlling-misuse-and-abuse [Last accessed 6 October 2014]
   Google Scholar
• Duh MS, Vekeman F, Korves C, et al. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications. Pain Med 2010;11(11):1718-25
   PubMedGoogle Scholar
• Summary minutes of the joint meeting of the drug safety and risk management advisory committee, nonprescription drugs advisory committee, and the anesthetic and life support drugs advisory committee of the U.S. food and drug administration to address the public health problem of liver injury related to the use of acetaminophen in both over-the-counter and prescription products. Held June 29 and 30, 2009 at Adelphi, MD. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM179888.pdf
   Google Scholar
• Acetaminophen overdose. Available from: http://www.nlm.nih.gov/medlineplus/ency/article/002598.htm
   Google Scholar
• Mort JR, Shiyanbola OO, Ndehi LN, et al. Opioid-paracetamol prescription patterns and liver dysfunction: A retrospective cohort study in a population served by a US health benefits organization. Drug Saf 2011;34(11):1079-88
   PubMedGoogle Scholar
• FDA drug safety communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. Available from: http://www.fda.gov/drugs/drugsafety/ucm239821.htm
   Google Scholar
• Blieden M, Paramore LC, Shah D, Ben-Joseph R. A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol 2014;7(3):341-8
   PubMed Web of Science ®Google Scholar
• Harris SC, Colucci SV, Perrino P, et al. A single-center, randomized, double-blind, crossover study to evaluate the abuse potential, pharmacokinetics, and safety of oral milled and intact extended-release hydrocodone (HYD) in recreational opioid users [abstract 440]. J Pain 2014;15(4):S86
   Google Scholar
• Harris SC, Colucci SV, Perrino P, et al. A single-center, randomized, double-blind, crossover study to evaluate the abuse potential, pharmacokinetics, and safety of milled and intranasally administered extended-release hydrocodone (HYD) tablets in recreational opioid users [abstract 440]. J Pain 2014;15(4):S86
   Google Scholar
• Loisel P, Vachon B, Lemaire J, et al. Discriminative and predictive validity assessment of the Quebec task force classification. Spine (Phila Pa 1976) 2002;27(8):851-7
   Google Scholar
• Spitzer W. Scientific approach to the assessment and measurement of activity-related spinal disorders. A monograph for clinicians. Report of the Quebec task force on spinal disorders. Spine (Phila Pa 1976) 1987;12(7 Suppl):S1-9
   Google Scholar
• Werneke MW, Hart DL. Categorizing patients with occupational low back pain by use of the Quebec task force classification system versus pain pattern classification procedures: Discriminant and predictive validity. Phys Ther 2004;84(3):243-54
   Web of Science ®Google Scholar
• Hays R, Stewart A. Sleep measures. In: Stewart A, Ware JJ, editors. Measuring functioning and well-being: the medical outcomes study approach. Duke University Press; Durham, NC: 1992. p. 235-59
   Google Scholar
• Farrar JT, Young JPJr, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94(2):149-58
   PubMed Web of Science ®Google Scholar
• Fairbank JC, Pynsent PB. The oswestry disability index. Spine (Philadelphia PA 1976) 2000;25(22):2940-52; discussion 2952
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: Global use of the brief pain inventory. Ann Acad Med Singapore 1994;23(2):129-38
   PubMedGoogle Scholar
• Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases. Pain 1983;17(2):197-210
   PubMed Web of Science ®Google Scholar
• Hoffman D, Friedman M, Colucci S, et al. Validation of the brief pain inventory for subjects with osteoarthritis. J Pain 2002;3:2 Supp 1
   Google Scholar
• Ware JEJr. SF-36 health survey update. Spine (Philadelphia, PA 1976) 2000;25(24):3130-9
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003;35(2):253-9
   PubMed Web of Science ®Google Scholar
• Butler SF, Fernandez K, Benoit C, et al. Validation of the revised screener and opioid assessment for patients with pain (SOAPP-R). J Pain 2008;9(4):360-72
   PubMed Web of Science ®Google Scholar
• Wu SM, Compton P, Bolus R, et al. The addiction behaviors checklist: Validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage 2006;32(4):342-51
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain 2010;26(9):770-6
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain 2007;130(1-2):144-56
   PubMed Web of Science ®Google Scholar
• Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician 2007;10(3):467-72
   PubMedGoogle Scholar
• Friedman RA, Adir Y, Crenshaw EB, et al. A transgenic insertional inner ear mutation on mouse chromosome 1. Laryngoscope 2000;110(4):489-96
   Google Scholar
• Oh AK, Ishiyama A, Baloh RW. Deafness associated with abuse of hydrocodone/acetaminophen. Neurology 2000;54(12):2345
   PubMed Web of Science ®Google Scholar
• Schweitzer VG, Darrat I, Stach BA, Gray E. Sudden bilateral sensorineural hearing loss following polysubstance narcotic overdose. J Am Acad Audiol 2011;22(4):208-14
   Google Scholar
• Yorgason JG, Kalinec GM, Luxford WM, et al. Acetaminophen ototoxicity after acetaminophen/hydrocodone abuse: Evidence from two parallel in vitro mouse models. Otolaryngol Head Neck Surg 2010;142(6):814-19
   Google Scholar
• Curhan SG, Eavey R, Shargorodsky J, Curhan GC. Analgesic use and the risk of hearing loss in men. Am J Med 2010;123(3):231-7
   PubMed Web of Science ®Google Scholar
• Curhan SG, Shargorodsky J, Eavey R, Curhan GC. Analgesic use and the risk of hearing loss in women. Am J Epidemiol 2012;176(6):544-54
   PubMedGoogle Scholar
• Calibration of speech signals delivered via earphones [Internet]. 1987. Available from: http://www.asha.org/policy/RP1987-00019.htm
   Google Scholar
• Carhart R, Jerger J. Preferred methods for clinical determination of pure-tone thresholds. J Speech Hear Res 1959;24:330-45
   Google Scholar
• Jerger J. Clinical experience with impendance audiometry. Arch Otolaryngol 1970;92(4):311-24
   PubMedGoogle Scholar
• Determining threshold level for speech [Internet]. 1988. Available from: www.asha.org/policy/GL1988-00008.htm
   Google Scholar
• Jacobson GP, Newman CW. The development of the dizziness handicap inventory. Arch Otolaryngol Head Neck Surg 1990;116(4):424-7
   PubMedGoogle Scholar
• Tamber AL, Wilhelmsen KT, Strand LI. Measurement properties of the dizziness handicap inventory by cross-sectional and longitudinal designs. Health Qual Life Outcomes 2009;7:101
   PubMed Web of Science ®Google Scholar
• Whitney SL, Wrisley DM, Brown KE, Furman JM. Is perception of handicap related to functional performance in persons with vestibular dysfunction? Otol Neurotol 2004;25(2):139-43
   PubMed Web of Science ®Google Scholar
• McCombe A, Baguley D, Coles R, et al. Guidelines for the grading of tinnitus severity: The results of a working group commissioned by the British association of otolaryngologists, head and neck surgeons, 1999. Clin Otolaryngol Allied Sci 2001;26(5):388-93
   PubMed Web of Science ®Google Scholar
• Newman CW, Jacobson GP, Spitzer JB. Development of the tinnitus handicap inventory. Arch Otolaryngol Head Neck Surg 1996;122(2):143-8
   PubMed Web of Science ®Google Scholar
• Clark JG. Uses and abuses of hearing loss classification. ASHA 1981;23(7):493-500
   PubMedGoogle Scholar
• Farrar JT, Dworkin RH, Max MB. Use of the cumulative proportion of responders analysis graph to present pain data over a range of cut-off points: Making clinical trial data more understandable. J Pain Symptom Manage 2006;31(4):369-77
   PubMed Web of Science ®Google Scholar
• National Research Council. The prevention and treatment of missing data in clinical trials. Panel on handling missing data in clinical trials. Committee on national statistics, division of behavioral and social sciences and education. The National Academies Press; Washington, DC: 2010
   Google Scholar
• Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: A randomized double-blind, placebo-controlled study. Pain Med 2014;15(6):975-85
   PubMed Web of Science ®Google Scholar
• Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122(4):112-28
   PubMed Web of Science ®Google Scholar
• Friedmann N, Klutzaritz V, Webster L. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. J Opioid Manag 2011;7(3):193-202
   PubMedGoogle Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: Results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6(1):21-8
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: A 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8(2):175-84
   PubMed Web of Science ®Google Scholar
• Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin 2007;23(1):117-28
   PubMed Web of Science ®Google Scholar
• Wen W, Taber L, Lynch S, et al. 12-month safety and effectiveness of once-daily hydrocodone tables formulated with abuse-deterrent properties in patients with moderate to severe chronic pain. J Opioid Manag; In press
   Google Scholar
• Hysingla ER. [package insert]. Purdue Pharma L.P; Stamford, CT: 2014
   Google Scholar